Safety, tolerability, immunogenicity, and plasmapheresis-based antibody collection in a phase 1b open label trial of two investigational monovalent chimpanzee adenoviral vectored filovirus vaccines, cAd3-Sudan and cAd3-Marburg, in healthy adultsResearch in context

Summary: Background: Sudan virus and Marburg virus are high priority biological threat pathogens with fatality rates of 25–90%. Recent outbreaks in Uganda, Equatorial Guinea, and Rwanda between 2022 and 2025 emphasise the critical need for effective vaccines. The aim of this phase 1b study was to d...

Full description

Bibliographic Details

Published in:	EBioMedicine
Main Authors:	Ekaterina Vert-Wong, Michael E. Stevenson, Roxana Rustomjee, Courtney L. Finch, Jocelyn Jakubik, Thomas H. King
Format:	Article
Language:	English
Published:	Elsevier 2025-09-01
Subjects:	cAd3-Marburg cAd3-Sudan cAd3-EBO-S Filovirus vaccine MARV SUDV
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396425003330